NASDAQ Framework: Tandem Diabetes Care Inc.

Insulin delivery and diabetes technology company 1 2.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship products include the t:slim X2 insulin delivery system and the Tandem Mobi insulin pump, both of which are designed to manage insulin delivery and integrate with continuous glucose monitoring systems. Tandem also offers a range of single-use products such as cartridges and infusion sets, as well as software solutions like the Tandem Device Updater and the Sugarmate mobile app. Headquartered in San Diego, California, Tandem Diabetes Care is committed to enhancing the quality of life for people with diabetes through innovative technology and comprehensive support 3 4.

3: Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. View Source4: We create new possibilities for people living with diabetes, their loved ones, and the healthcare providers supporting them. Products Tandem Mobi SystemImpressively small, iPhone controlLearn More t:slim X2 Insulin PumpProven system, color touchscreenLearn More Back Powerful System Automated Insulin Delivery Glucose Monitoring Software & Mobile Apps Software & Mobile Apps Our integrated platforms bring together automated insulin delivery, therapy data, software updates, and other technology. Software & Mobile Apps Free Virtual Pump Demo Mobile Apps Tandem Source Remote Software Updates Sugarmate Infusion Sets Accessories Why Tandem Community Community We love the supportive diabetes community. That’s why Tandem Diabetes Care is active on social media and at local events. Back Supportive Community Join Team Tandem Team Tandem Spotlight Tandem Blog Event Calendar Advocacy Launchpad Support Support Tandem Diabetes Care has your back with 24/7 technical support and a wide range of trainings, services, and resources. Back Connected Care Get Help Diabetes Education Diabetes Education These articles are designed to help educate about diabetes, diabetes management, and insulin pump therapy. Diabetes Education Type 1 Diabetes Type 2 Diabetes Managing Diabetes Nutrition View All Categories Pump Training Available Software Updates Pump Benefit Programs Providers Get Started Back Account Login Tandem Source Search View Source

UNKNOWN

The provided facts do not specify whether the founders of Tandem Diabetes Care Inc. are still leading the company or are heavily involved in its operations. The information available only mentions the current executives and their roles 5 6 7 8.

5: Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 SAN DIEGO, July 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. Business Wire • 11 days ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes Zacks • 21 days ago TNDM +1.85% Tandem showcases data from user survey of Tandem Mobi Of the patients, 86% said they were satisfied or very satisfied with Mobi and agreed that it helps improve their quality of life. Medical Device Network • 29 days ago TNDM +1.85% Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions SAN DIEGO, June 22, 2024--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions. Business Wire • last month TNDM +1.85% Tandem names Jean-Claude Kyrillos as chief operating officer The appointment gives Kyrillos a leading role in work to expand the insulin delivery company’s global operations and achieve profitable growth. MedTech Dive • last month TNDM +1.85% NVST Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer SAN DIEGO, June 20, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. Business Wire • last month TNDM +1.85% The 3 Best Diabetes Stocks to Buy in June 2024 Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they InvestorPlace • last month DXCM +0.59% PODD +1.97% TNDM +1.85% Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions SAN DIEGO, June 18, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Business Wire • last month TNDM +1.85% Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks • last month OPK TNDM +1.85% Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM). Zacks • last month TNDM +1.85% At US$51.23, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely? Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ), might not be a large cap stock, but it saw a significant share price rise... Simply Wall St. • last month TNDM +1.85% Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM. Zacks • last month TNDM +1.85% DXCM +0.59% Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system1, launched in the United States earlier this year. Business Wire • last month DXCM +0.59% TNDM +1.85% Tandem Diabetes Care Announces Upcoming Conference Presentation SAN DIEGO, May 23, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:00am Eastern Time (5:00am Pacific Time). Business Wire • last month TNDM +1.85% Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It? Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance. Zacks • 2 months ago TNDM +1.85% Earnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57 Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) investors will be delighted, with the company turning in some strong numbers... Simply Wall St. • 2 months ago TNDM +1.85% Why Tandem Diabetes Stock Just Jumped 22% Tandem Diabetes stock is showing great growth -- but miserable profits. Motley Fool • 2 months ago TNDM +1.85% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript May 2, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0.65387, expectations were $-0.8. Tandem Diabetes Care, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […] Insider Monkey • 2 months ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi. Zacks • 2 months ago TNDM +1.85% Q1 2024 Tandem Diabetes Care Inc Earnings Call Q1 2024 Tandem Diabetes Care Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago TNDM +1.85% View Source6: Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 Business Wire Jul 11, 2024 8:05pm Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions Business Wire Jun 22, 2024 3:00pm Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer Business Wire Jun 20, 2024 1:00pm Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions Business Wire Jun 18, 2024 1:00pm Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM Business Wire May 29, 2024 12:30pm Tandem Diabetes Care Announces Upcoming Conference Presentation Business Wire May 23, 2024 8:05pm Tandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial Guidance Business Wire May 2, 2024 8:05pm Tandem Diabetes Care Announces Upcoming Conference Presentations Business Wire Apr 29, 2024 8:05pm View Source7: Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. View Source8: Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer View Source

MEDIUM RISK

Tandem Diabetes Care Inc. has shown positive developments, such as the launch of the Tandem Mobi insulin pump and its compatibility with Dexcom G7 CGM, which bodes well for future growth 9 10. The company has also posted positive data and user satisfaction for its products 11 12. However, the company has not yet achieved consistent positive earnings and still has a few years to go to establish itself as a major competitor 13. Additionally, the company has a mixed financial strength rating and a target price that suggests moderate growth potential 14 15. Therefore, the financial situation of Tandem Diabetes Care Inc. can be considered medium risk.

9: Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. View Source10: Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor View Source11: Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi View Source12: Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions View Source13: Though Tandem Diabetes has made a splash in the insulin pump market as the latest entrant in the US, the firm is still endeavoring to establish itself as a major competitor. On this rather lengthy path between the initial 2012 launch of its original t:slim pump and consistent positive earnings, Tandem still has a few years to go, from our perspective. View Source14: Raising target price to $49.00 TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 4 days ago Tandem Earnings: Launch of Mobi and CGM Integrations Bodes Well for 2024 Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. Rating Price Target Morningstar• 10 days ago Raising target price to $45.00 TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 11 days ago Rating increased to a HOLD TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 18 days ago View Source15: Redburn Atlantic raised the price target for the Tandem Diabetes Care Inc (NASDAQ:TNDM) stock to “a Buy”. The rating was released on May 30, 2024, according to finviz. We previously noted in another research note published on May 22, 2024 by Citigroup that upgraded the stock from a Neutral to a Buy with a price target of $57 for TNDM stock. The research report from Wells Fargo has upgraded the stock from Equal Weight to Overweight, with a price target set at $45. The stock was upgraded by Leerink Partners, who disclosed in a research note on April 25, 2024, from Market Perform to Outperform and set the price objective to $45. In their research brief published March 26, 2024, Stifel analysts upgraded the Tandem Diabetes Care Inc stock from Hold to Buy with a price target of $37. View Source

YES

Tandem Diabetes Care Inc. is launching new product offerings. Specifically, the company has recently launched the Tandem Mobi insulin pump and is working on a tubeless pump 16 17.

16: Raising target price to $49.00 TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 4 days ago Tandem Earnings: Launch of Mobi and CGM Integrations Bodes Well for 2024 Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. Rating Price Target Morningstar• 10 days ago Raising target price to $45.00 TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 11 days ago Rating increased to a HOLD TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 18 days ago View Source17: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. View Source

Tandem Diabetes Care Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focus on leveraging their innovative insulin delivery systems and expanding their global operations. The company plans to continue enhancing its flagship products, the t:slim X2 insulin delivery system and the Tandem Mobi insulin pump, which now integrates with the Dexcom G7 CGM 18 19. Additionally, Tandem is working on developing a tubeless pump to further diversify its product offerings 20. The appointment of Jean-Claude Kyrillos as Chief Operating Officer underscores Tandem's commitment to expanding its global footprint and achieving profitable growth 21 22. The company also aims to maintain its strong market presence by continuously improving user satisfaction and product performance, as evidenced by the positive feedback from the Tandem Mobi user survey 23 24.

18: Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. View Source19: Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor View Source20: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. View Source21: Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 SAN DIEGO, July 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. Business Wire • 11 days ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes Zacks • 21 days ago TNDM +1.85% Tandem showcases data from user survey of Tandem Mobi Of the patients, 86% said they were satisfied or very satisfied with Mobi and agreed that it helps improve their quality of life. Medical Device Network • 29 days ago TNDM +1.85% Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions SAN DIEGO, June 22, 2024--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions. Business Wire • last month TNDM +1.85% Tandem names Jean-Claude Kyrillos as chief operating officer The appointment gives Kyrillos a leading role in work to expand the insulin delivery company’s global operations and achieve profitable growth. MedTech Dive • last month TNDM +1.85% NVST Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer SAN DIEGO, June 20, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. Business Wire • last month TNDM +1.85% The 3 Best Diabetes Stocks to Buy in June 2024 Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they InvestorPlace • last month DXCM +0.59% PODD +1.97% TNDM +1.85% Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions SAN DIEGO, June 18, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Business Wire • last month TNDM +1.85% Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks • last month OPK TNDM +1.85% Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM). Zacks • last month TNDM +1.85% At US$51.23, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely? Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ), might not be a large cap stock, but it saw a significant share price rise... Simply Wall St. • last month TNDM +1.85% Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM. Zacks • last month TNDM +1.85% DXCM +0.59% Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system1, launched in the United States earlier this year. Business Wire • last month DXCM +0.59% TNDM +1.85% Tandem Diabetes Care Announces Upcoming Conference Presentation SAN DIEGO, May 23, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:00am Eastern Time (5:00am Pacific Time). Business Wire • last month TNDM +1.85% Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It? Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance. Zacks • 2 months ago TNDM +1.85% Earnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57 Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) investors will be delighted, with the company turning in some strong numbers... Simply Wall St. • 2 months ago TNDM +1.85% Why Tandem Diabetes Stock Just Jumped 22% Tandem Diabetes stock is showing great growth -- but miserable profits. Motley Fool • 2 months ago TNDM +1.85% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript May 2, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0.65387, expectations were $-0.8. Tandem Diabetes Care, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […] Insider Monkey • 2 months ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi. Zacks • 2 months ago TNDM +1.85% Q1 2024 Tandem Diabetes Care Inc Earnings Call Q1 2024 Tandem Diabetes Care Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago TNDM +1.85% View Source22: Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer View Source23: Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 SAN DIEGO, July 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. Business Wire • 11 days ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes Zacks • 21 days ago TNDM +1.85% Tandem showcases data from user survey of Tandem Mobi Of the patients, 86% said they were satisfied or very satisfied with Mobi and agreed that it helps improve their quality of life. Medical Device Network • 29 days ago TNDM +1.85% Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions SAN DIEGO, June 22, 2024--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions. Business Wire • last month TNDM +1.85% Tandem names Jean-Claude Kyrillos as chief operating officer The appointment gives Kyrillos a leading role in work to expand the insulin delivery company’s global operations and achieve profitable growth. MedTech Dive • last month TNDM +1.85% NVST Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer SAN DIEGO, June 20, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. Business Wire • last month TNDM +1.85% The 3 Best Diabetes Stocks to Buy in June 2024 Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they InvestorPlace • last month DXCM +0.59% PODD +1.97% TNDM +1.85% Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions SAN DIEGO, June 18, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Business Wire • last month TNDM +1.85% Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks • last month OPK TNDM +1.85% Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM). Zacks • last month TNDM +1.85% At US$51.23, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely? Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ), might not be a large cap stock, but it saw a significant share price rise... Simply Wall St. • last month TNDM +1.85% Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM. Zacks • last month TNDM +1.85% DXCM +0.59% Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system1, launched in the United States earlier this year. Business Wire • last month DXCM +0.59% TNDM +1.85% Tandem Diabetes Care Announces Upcoming Conference Presentation SAN DIEGO, May 23, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:00am Eastern Time (5:00am Pacific Time). Business Wire • last month TNDM +1.85% Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It? Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance. Zacks • 2 months ago TNDM +1.85% Earnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57 Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) investors will be delighted, with the company turning in some strong numbers... Simply Wall St. • 2 months ago TNDM +1.85% Why Tandem Diabetes Stock Just Jumped 22% Tandem Diabetes stock is showing great growth -- but miserable profits. Motley Fool • 2 months ago TNDM +1.85% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript May 2, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0.65387, expectations were $-0.8. Tandem Diabetes Care, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […] Insider Monkey • 2 months ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi. Zacks • 2 months ago TNDM +1.85% Q1 2024 Tandem Diabetes Care Inc Earnings Call Q1 2024 Tandem Diabetes Care Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago TNDM +1.85% View Source24: Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi View Source

Sources

1: Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 SAN DIEGO, July 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. Business Wire • 11 days ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes Zacks • 21 days ago TNDM +1.85% Tandem showcases data from user survey of Tandem Mobi Of the patients, 86% said they were satisfied or very satisfied with Mobi and agreed that it helps improve their quality of life. Medical Device Network • 29 days ago TNDM +1.85% Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions SAN DIEGO, June 22, 2024--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions. Business Wire • last month TNDM +1.85% Tandem names Jean-Claude Kyrillos as chief operating officer The appointment gives Kyrillos a leading role in work to expand the insulin delivery company’s global operations and achieve profitable growth. MedTech Dive • last month TNDM +1.85% NVST Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer SAN DIEGO, June 20, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. Business Wire • last month TNDM +1.85% The 3 Best Diabetes Stocks to Buy in June 2024 Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they InvestorPlace • last month DXCM +0.59% PODD +1.97% TNDM +1.85% Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions SAN DIEGO, June 18, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Business Wire • last month TNDM +1.85% Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks • last month OPK TNDM +1.85% Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM). Zacks • last month TNDM +1.85% At US$51.23, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely? Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ), might not be a large cap stock, but it saw a significant share price rise... Simply Wall St. • last month TNDM +1.85% Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM. Zacks • last month TNDM +1.85% DXCM +0.59% Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system1, launched in the United States earlier this year. Business Wire • last month DXCM +0.59% TNDM +1.85% Tandem Diabetes Care Announces Upcoming Conference Presentation SAN DIEGO, May 23, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:00am Eastern Time (5:00am Pacific Time). Business Wire • last month TNDM +1.85% Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It? Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance. Zacks • 2 months ago TNDM +1.85% Earnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57 Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) investors will be delighted, with the company turning in some strong numbers... Simply Wall St. • 2 months ago TNDM +1.85% Why Tandem Diabetes Stock Just Jumped 22% Tandem Diabetes stock is showing great growth -- but miserable profits. Motley Fool • 2 months ago TNDM +1.85% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript May 2, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0.65387, expectations were $-0.8. Tandem Diabetes Care, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […] Insider Monkey • 2 months ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi. Zacks • 2 months ago TNDM +1.85% Q1 2024 Tandem Diabetes Care Inc Earnings Call Q1 2024 Tandem Diabetes Care Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago TNDM +1.85% View Source2: Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. View Source3: Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. View Source4: We create new possibilities for people living with diabetes, their loved ones, and the healthcare providers supporting them. Products Tandem Mobi SystemImpressively small, iPhone controlLearn More t:slim X2 Insulin PumpProven system, color touchscreenLearn More Back Powerful System Automated Insulin Delivery Glucose Monitoring Software & Mobile Apps Software & Mobile Apps Our integrated platforms bring together automated insulin delivery, therapy data, software updates, and other technology. Software & Mobile Apps Free Virtual Pump Demo Mobile Apps Tandem Source Remote Software Updates Sugarmate Infusion Sets Accessories Why Tandem Community Community We love the supportive diabetes community. That’s why Tandem Diabetes Care is active on social media and at local events. Back Supportive Community Join Team Tandem Team Tandem Spotlight Tandem Blog Event Calendar Advocacy Launchpad Support Support Tandem Diabetes Care has your back with 24/7 technical support and a wide range of trainings, services, and resources. Back Connected Care Get Help Diabetes Education Diabetes Education These articles are designed to help educate about diabetes, diabetes management, and insulin pump therapy. Diabetes Education Type 1 Diabetes Type 2 Diabetes Managing Diabetes Nutrition View All Categories Pump Training Available Software Updates Pump Benefit Programs Providers Get Started Back Account Login Tandem Source Search View Source5: Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 SAN DIEGO, July 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. Business Wire • 11 days ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes Zacks • 21 days ago TNDM +1.85% Tandem showcases data from user survey of Tandem Mobi Of the patients, 86% said they were satisfied or very satisfied with Mobi and agreed that it helps improve their quality of life. Medical Device Network • 29 days ago TNDM +1.85% Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions SAN DIEGO, June 22, 2024--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions. Business Wire • last month TNDM +1.85% Tandem names Jean-Claude Kyrillos as chief operating officer The appointment gives Kyrillos a leading role in work to expand the insulin delivery company’s global operations and achieve profitable growth. MedTech Dive • last month TNDM +1.85% NVST Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer SAN DIEGO, June 20, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. Business Wire • last month TNDM +1.85% The 3 Best Diabetes Stocks to Buy in June 2024 Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they InvestorPlace • last month DXCM +0.59% PODD +1.97% TNDM +1.85% Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions SAN DIEGO, June 18, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Business Wire • last month TNDM +1.85% Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks • last month OPK TNDM +1.85% Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM). Zacks • last month TNDM +1.85% At US$51.23, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely? Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ), might not be a large cap stock, but it saw a significant share price rise... Simply Wall St. • last month TNDM +1.85% Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM. Zacks • last month TNDM +1.85% DXCM +0.59% Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system1, launched in the United States earlier this year. Business Wire • last month DXCM +0.59% TNDM +1.85% Tandem Diabetes Care Announces Upcoming Conference Presentation SAN DIEGO, May 23, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:00am Eastern Time (5:00am Pacific Time). Business Wire • last month TNDM +1.85% Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It? Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance. Zacks • 2 months ago TNDM +1.85% Earnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57 Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) investors will be delighted, with the company turning in some strong numbers... Simply Wall St. • 2 months ago TNDM +1.85% Why Tandem Diabetes Stock Just Jumped 22% Tandem Diabetes stock is showing great growth -- but miserable profits. Motley Fool • 2 months ago TNDM +1.85% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript May 2, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0.65387, expectations were $-0.8. Tandem Diabetes Care, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […] Insider Monkey • 2 months ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi. Zacks • 2 months ago TNDM +1.85% Q1 2024 Tandem Diabetes Care Inc Earnings Call Q1 2024 Tandem Diabetes Care Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago TNDM +1.85% View Source6: Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 Business Wire Jul 11, 2024 8:05pm Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions Business Wire Jun 22, 2024 3:00pm Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer Business Wire Jun 20, 2024 1:00pm Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions Business Wire Jun 18, 2024 1:00pm Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM Business Wire May 29, 2024 12:30pm Tandem Diabetes Care Announces Upcoming Conference Presentation Business Wire May 23, 2024 8:05pm Tandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial Guidance Business Wire May 2, 2024 8:05pm Tandem Diabetes Care Announces Upcoming Conference Presentations Business Wire Apr 29, 2024 8:05pm View Source7: Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. View Source8: Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer View Source9: Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. View Source10: Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor View Source11: Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi View Source12: Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions View Source13: Though Tandem Diabetes has made a splash in the insulin pump market as the latest entrant in the US, the firm is still endeavoring to establish itself as a major competitor. On this rather lengthy path between the initial 2012 launch of its original t:slim pump and consistent positive earnings, Tandem still has a few years to go, from our perspective. View Source14: Raising target price to $49.00 TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 4 days ago Tandem Earnings: Launch of Mobi and CGM Integrations Bodes Well for 2024 Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. Rating Price Target Morningstar• 10 days ago Raising target price to $45.00 TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 11 days ago Rating increased to a HOLD TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 18 days ago View Source15: Redburn Atlantic raised the price target for the Tandem Diabetes Care Inc (NASDAQ:TNDM) stock to “a Buy”. The rating was released on May 30, 2024, according to finviz. We previously noted in another research note published on May 22, 2024 by Citigroup that upgraded the stock from a Neutral to a Buy with a price target of $57 for TNDM stock. The research report from Wells Fargo has upgraded the stock from Equal Weight to Overweight, with a price target set at $45. The stock was upgraded by Leerink Partners, who disclosed in a research note on April 25, 2024, from Market Perform to Outperform and set the price objective to $45. In their research brief published March 26, 2024, Stifel analysts upgraded the Tandem Diabetes Care Inc stock from Hold to Buy with a price target of $37. View Source16: Raising target price to $49.00 TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 4 days ago Tandem Earnings: Launch of Mobi and CGM Integrations Bodes Well for 2024 Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. Rating Price Target Morningstar• 10 days ago Raising target price to $45.00 TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 11 days ago Rating increased to a HOLD TANDEM DIABETES CARE INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium. Rating Price Target Argus• 18 days ago View Source17: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. View Source18: Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. View Source19: Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor View Source20: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. View Source21: Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 SAN DIEGO, July 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. Business Wire • 11 days ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes Zacks • 21 days ago TNDM +1.85% Tandem showcases data from user survey of Tandem Mobi Of the patients, 86% said they were satisfied or very satisfied with Mobi and agreed that it helps improve their quality of life. Medical Device Network • 29 days ago TNDM +1.85% Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions SAN DIEGO, June 22, 2024--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions. Business Wire • last month TNDM +1.85% Tandem names Jean-Claude Kyrillos as chief operating officer The appointment gives Kyrillos a leading role in work to expand the insulin delivery company’s global operations and achieve profitable growth. MedTech Dive • last month TNDM +1.85% NVST Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer SAN DIEGO, June 20, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. Business Wire • last month TNDM +1.85% The 3 Best Diabetes Stocks to Buy in June 2024 Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they InvestorPlace • last month DXCM +0.59% PODD +1.97% TNDM +1.85% Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions SAN DIEGO, June 18, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Business Wire • last month TNDM +1.85% Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks • last month OPK TNDM +1.85% Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM). Zacks • last month TNDM +1.85% At US$51.23, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely? Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ), might not be a large cap stock, but it saw a significant share price rise... Simply Wall St. • last month TNDM +1.85% Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM. Zacks • last month TNDM +1.85% DXCM +0.59% Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system1, launched in the United States earlier this year. Business Wire • last month DXCM +0.59% TNDM +1.85% Tandem Diabetes Care Announces Upcoming Conference Presentation SAN DIEGO, May 23, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:00am Eastern Time (5:00am Pacific Time). Business Wire • last month TNDM +1.85% Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It? Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance. Zacks • 2 months ago TNDM +1.85% Earnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57 Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) investors will be delighted, with the company turning in some strong numbers... Simply Wall St. • 2 months ago TNDM +1.85% Why Tandem Diabetes Stock Just Jumped 22% Tandem Diabetes stock is showing great growth -- but miserable profits. Motley Fool • 2 months ago TNDM +1.85% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript May 2, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0.65387, expectations were $-0.8. Tandem Diabetes Care, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […] Insider Monkey • 2 months ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi. Zacks • 2 months ago TNDM +1.85% Q1 2024 Tandem Diabetes Care Inc Earnings Call Q1 2024 Tandem Diabetes Care Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago TNDM +1.85% View Source22: Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer View Source23: Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 SAN DIEGO, July 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. Business Wire • 11 days ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes Zacks • 21 days ago TNDM +1.85% Tandem showcases data from user survey of Tandem Mobi Of the patients, 86% said they were satisfied or very satisfied with Mobi and agreed that it helps improve their quality of life. Medical Device Network • 29 days ago TNDM +1.85% Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions SAN DIEGO, June 22, 2024--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions. Business Wire • last month TNDM +1.85% Tandem names Jean-Claude Kyrillos as chief operating officer The appointment gives Kyrillos a leading role in work to expand the insulin delivery company’s global operations and achieve profitable growth. MedTech Dive • last month TNDM +1.85% NVST Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer SAN DIEGO, June 20, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. Business Wire • last month TNDM +1.85% The 3 Best Diabetes Stocks to Buy in June 2024 Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they InvestorPlace • last month DXCM +0.59% PODD +1.97% TNDM +1.85% Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions SAN DIEGO, June 18, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Business Wire • last month TNDM +1.85% Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks • last month OPK TNDM +1.85% Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM). Zacks • last month TNDM +1.85% At US$51.23, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely? Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ), might not be a large cap stock, but it saw a significant share price rise... Simply Wall St. • last month TNDM +1.85% Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM. Zacks • last month TNDM +1.85% DXCM +0.59% Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system1, launched in the United States earlier this year. Business Wire • last month DXCM +0.59% TNDM +1.85% Tandem Diabetes Care Announces Upcoming Conference Presentation SAN DIEGO, May 23, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:00am Eastern Time (5:00am Pacific Time). Business Wire • last month TNDM +1.85% Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It? Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance. Zacks • 2 months ago TNDM +1.85% Earnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57 Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) investors will be delighted, with the company turning in some strong numbers... Simply Wall St. • 2 months ago TNDM +1.85% Why Tandem Diabetes Stock Just Jumped 22% Tandem Diabetes stock is showing great growth -- but miserable profits. Motley Fool • 2 months ago TNDM +1.85% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call Transcript May 2, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0.65387, expectations were $-0.8. Tandem Diabetes Care, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […] Insider Monkey • 2 months ago TNDM +1.85% Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi. Zacks • 2 months ago TNDM +1.85% Q1 2024 Tandem Diabetes Care Inc Earnings Call Q1 2024 Tandem Diabetes Care Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago TNDM +1.85% View Source24: Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi View Source